keyword
MENU ▼
Read by QxMD icon Read
search

bioresorbable vascular scaffold

keyword
https://www.readbyqxmd.com/read/28913627/everolimus-eluting-bioresorbable-vascular-scaffold-in-daily-clinical-practice-a%C3%A2-single-centre-experience
#1
W S Remkes, R S Hermanides, M W Kennedy, E Fabris, E Kaplan, J P Ottervanger, A W J van 't Hof, E Kedhi
BACKGROUND: Recent evidence has raised concerns regarding the safety of the everolimus-eluting bioresorbable vascular scaffold (E-BVS) (Absorb, Abbott Vascular, Santa Clara, CA, USA). Following these data, the use of this device has diminished in the Netherlands; however, daily practice data are limited. Therefore we studied the incidence of safety and efficacy outcomes with this device in daily clinical practice in a single large tertiary centre in the Netherlands. METHODS: All E‑BVS treated patients were included in this analysis...
September 14, 2017: Netherlands Heart Journal
https://www.readbyqxmd.com/read/28899664/implant-for-autologous-soft-tissue-reconstruction-using-an-adipose-derived-stem-cell-colonized-alginate-scaffold
#2
Tobias Hirsch, Christine Laemmle, Bjoern Behr, Marcus Lehnhardt, Frank Jacobsen, Dirk Hoefer, Maximilian Kueckelhaus
BACKGROUND: Adipose-derived stem cells represent an interesting option for soft tissue replacement as they are easy to procure and can generate their own blood supply through the production of angiogenic factors. We seeded adipose-derived stem cells on a bioresorbable, biocompatible polymer alginate scaffold to generate autologous soft tissue constructs for repair. MATERIALS AND METHODS: We built and optimized an alginate scaffold and tested its biocompatibility using the MTT assay and its hydration capacity...
August 16, 2017: Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS
https://www.readbyqxmd.com/read/28898243/neoatherosclerosis-development-following-bioresorbable-vascular-scaffold-implantation-in-diabetic-and-non-diabetic-swine
#3
Nienke S van Ditzhuijzen, Mie Kurata, Mieke van den Heuvel, Oana Sorop, Richard W B van Duin, Ilona Krabbendam-Peters, Jurgen Ligthart, Karen Witberg, Magdalena Murawska, Brett Bouma, Martin Villiger, Hector M Garcia-Garcia, Patrick W Serruys, Felix Zijlstra, Gijs van Soest, Dirk-Jan Duncker, Evelyn Regar, Heleen M M van Beusekom
BACKGROUND: DM remains a risk factor for poor outcome after stent-implantation, but little is known if and how DM affects the vascular response to BVS. AIM: The aim of our study was to examine coronary responses to bioresorbable vascular scaffolds (BVS) in swine with and without diabetes mellitus fed a 'fast-food' diet (FF-DM and FF-NDM, respectively) by sequential optical coherence tomography (OCT)-imaging and histology. METHODS: Fifteen male swine were evaluated...
2017: PloS One
https://www.readbyqxmd.com/read/28894605/optical-coherence-tomography-guidance-during-bioresorbable-vascular-scaffold-implantation
#4
REVIEW
Gioel Gabrio Secco, Monica Verdoia, Gianfranco Pistis, Giuseppe De Luca, Matteo Vercellino, Andrea Audo, Rosario Parisi, Maurizio Reale, Giorgio Ballestrero, Paolo Nicola Marino, Carlo Di Mario
Bioresorbable vascular scaffold (BRS) represent a revolutionary concept in interventional cardiology. After initial enthusiasm, recent real world registries, including patients with increasing lesion complexity, reported not trivial rates of scaffold thrombosis (ScT). The importance of correct patients selection as well as technical aspects during BRS implantation procedures has been highlighted in several studies suggesting that the high rate of ScT might be related to uncorrected patients/lesions selection together with underutilization of intracoronary imaging guidance leading to suboptimal BRS implantation...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894603/are-acute-coronary-syndromes-an-ideal-scenario-for-bioresorbable-vascular-scaffold-implantation
#5
REVIEW
Elisabetta Moscarella, Alfonso Ielasi, Maria Carmen De Angelis, Fortunato Scotto di Uccio, Enrico Cerrato, Roberta De Rosa, Gianluca Campo, Attilio Varricchio
Bioresorbable vascular scaffolds (BRS) represent the latest innovation in the field of interventional cardiology. BRS have recently been introduced in routine clinical practice and their use has progressively extended in everyday clinical practice. The BRS use appears theoretically attractive in patients presenting with acute coronary syndromes (ACS) as they are generally young with long life expectancy, thus possibly benefiting more of the so-called vascular reparative therapy. Furthermore, "culprit" lesions are usually softer and more easily expandable by current BRS compared to stable chronic lesions...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894602/methods-to-assess-bioresorbable-vascular-scaffold-devices-behaviour-after-implantation
#6
REVIEW
Alberto Pernigotti, Elisabetta Moscarella, Giosafat Spitaleri, Claudia Scardino, Kohki Ishida, Salvatore Brugaletta
Bioresorbable vascular scaffolds (BRS) represent a novel approach for coronary revascularization offering several advantages as compared to current generation DES, potentially reducing rate of late adverse events and avoiding permanent vessel caging. Nevertheless, safety concerns have been raised for an increased risk of scaffold thrombosis (ScT) in both early and late phases, probably related to a suboptimal scaffold implantation. In this context, the use of different imaging methodologies has been strongly suggested in order to guarantee an optimal implantation...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894600/current-concepts-on-coronary-revascularization-using-brs-in-patients-with-diabetes-and-small-vessels-disease
#7
REVIEW
Giulia Masiero, Marco Mojoli, Daisuke Ueshima, Giuseppe Tarantini
Diabetes mellitus (DM) and small vessel (SV) disease are two major predictors of adverse outcome in patients treated by percutaneous coronary intervention (PCI), even when last generation metallic drug-eluting stents (DES) are used. Bioresorbable scaffold (BRS) technology has been recently developed to overcome the disadvantages of metallic DES due to their permanent struts. Through the resorption process, BRS may provide a vascular restoration that appears very attractive especially when distal or diffusely diseased coronary segments are involved, as in diabetic patients and SV disease...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894599/occurrence-and-management-of-bioresorbable-vascular-scaffold-failure-in-real-life-studies
#8
REVIEW
Bernardo Cortese, Mostafa Elwany
Bioresorbable vascular scaffold (BVS) has emerged as a new technology aiming at overcoming some drawbacks of the conventional metallic stent. In spite of the initial promising results, this technology stumbled upon numerous challenges, which were revealed in the real world studies. Thanks to real world trials and registries findings, our knowledge about the BVS has grown over time, thus we have understood on BVS behavior in various settings and formulated better implantation techniques. In this article, we will review the incidence of BVS failure in real world studies, its different etiologies and management strategies...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894597/brs-implantation-in-long-lesions-requiring-device-overlapping-myth-or-reality
#9
REVIEW
Simone Biscaglia, Andrea Erriquez, Davide Bernucci, Giulia Bugani, Enrico Favaretto, Gianluca Campo
Dealing with bioresorbable vascular scaffolds (BVS) implantation in long lesions requiring device overlapping in this particular moment might seem a little provocative for several reasons. First, most studies testing BVS have focused on their safety and efficacy profile in simple patients with simple lesions. Second, ABSORB II did not meet its primary endpoint, while ABSORB III showed a higher rate of target vessel-myocardial infarction (TV-MI) at 2 years. Third, data on porcine model showed that overlapping zone has delayed but greater neointimal proliferation with consequent higher risk for scaffold thrombosis in the short-term and of in-scaffold restenosis in the long-term...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894595/the-impact-of-the-3-year-absorb-ii-trial-results-on-my-clinical-practice-an-italian-survey
#10
Matteo Serenelli, Simone Biscaglia, Elisabetta Tonet, Arnaldo Poli, Elisa Nicolini, Alfonso Ielasi, Andrea Erriquez, Gianluca Campo
BACKGROUND: To evaluate how the 3-year results from the "A clinical evaluation to compare the safety, efficacy and performance of ABSORB everolimus eluting bioresorbable vascular scaffold (BVS) system against XIENCE everolimus eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions" (ABSORB II) trial have influenced clinical practice among Italian interventional cardiologists. METHODS: We performed a survey among 95 interventional cardiologists sending a brief questionnaire by electronic mail...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894594/effectiveness-and-safety-of-the-absorb-bioresorbable-vascular-scaffold-for-the-treatment-of-coronary-artery-disease-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#11
Rita Pavasini, Matteo Serenelli, Francesco Gallo, Giulia Bugani, Salvatore Geraci, Paolo Vicinelli, Gianluca Campo
BACKGROUND: In the last years bioresorbable vascular scaffold (BVS) become a new therapeutic option for interventional cardiologists, with the advantage of a scaffold inducing a possible vessel wall restoration. Nevertheless, several trials tried to prove the safety and efficacy profile of scaffolds, but with conflicting results. METHODS: A systematic review and meta-analysis was performed. The search was carried out in PubMed, Google Scholar, Biomed Central and Cochrane Library between January and March 2017...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28893770/serial-5-year-evaluation-of-side-branches-jailed-by-bioresorbable-vascular-scaffolds-using-3-dimensional-optical-coherence-tomography-insights-from-the-absorb-cohort-b-trial-a-clinical-evaluation-of-the-bioabsorbable-everolimus-eluting-coronary-stent-system
#12
Yoshinobu Onuma, Maik J Grundeken, Shimpei Nakatani, Taku Asano, Yohei Sotomi, Nicolas Foin, Jaryl Ng, Takayuki Okamura, Joanna J Wykrzykowska, Robbert J de Winter, Robert-Jan van Geuns, Jacques Koolen, Evald Christiansen, Robert Whitbourn, Dougal McClean, Pieter Smits, Stephan Windecker, John A Ormiston, Patrick W Serruys
BACKGROUND: The long-term fate of Absorb bioresorbable vascular scaffold (Abbott Vascular, Santa Clara, CA) struts jailing side branch ostia has not been clarified. We therefore evaluate serially (post-procedure and at 6 months, 1, 2, 3, and 5 years) the appearance and fate of jailed Absorb bioresorbable vascular scaffold struts. METHODS AND RESULTS: We performed 3-dimensional optical coherence tomographic analysis of the ABSORB Cohort B trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) up to 5 years using a novel, validated cut-plane analysis method...
September 2017: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28891161/comparison-of-acute-expansion-of-bioresorbable-vascular-scaffolds-versus-metallic-drug-eluting-stents-in-different-degrees-of-calcification-an-optical-coherence-tomography-study-doi-10-1002-ccd-26676
#13
(no author information available yet)
No abstract text is available yet for this article.
September 1, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28867010/mid-term-clinical-outcomes-of-absorb-bioresorbable-vascular-scaffold-versus-everolimus-eluting-stent-for-coronary-bifurcation-lesions
#14
Toru Naganuma, Hiroyoshi Kawamoto, Vasileios F Panoulas, Azeem Latib, Akihito Tanaka, Satoru Mitomo, Neil Ruparelia, Richard J Jabbour, Alaide Chieffo, Mauro Carlino, Matteo Montorfano, Antonio Colombo
BACKGROUND: Data regarding bioresorbable vascular scaffolds (BVS) use in coronary bifurcation lesions are limited. The aim of this study was to compare mid-term clinical outcomes of all-comer patients treated with BVS versus everolimus-eluting stents (EES) for bifurcation lesions. METHODS: A total of 351 non-left-main bifurcation lesions in 323 all-comer patients were treated either with BVS (166 bifurcations in 147 patients) or EES (185 bifurcations in 176 patients)...
November 1, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28866036/bioresorbable-vascular-scaffolds-for-patients-with-in-stent-restenosis-the-ribs-vi-study
#15
Fernando Alfonso, Javier Cuesta, María José Pérez-Vizcayno, Bruno García Del Blanco, José Ramón Rumoroso, Francisco Bosa, Armando Pérez de Prado, Mónica Masotti, Raul Moreno, Angel Cequier, Hipólito Gutiérrez, Arturo García Touchard, José Ramón López-Mínguez, Javier Zueco, Vicens Martí, Maite Velázquez, César Morís, Teresa Bastante, Marcos García-Guimaraes, Fernando Rivero, Cristina Fernández
OBJECTIVES: This study sought to assess the value of bioresorbable vascular scaffolds (BVS) in patients with in-stent restenosis (ISR). BACKGROUND: Currently both drug-eluting stents (DES) and drug-eluting balloons (DEB) are recommended in patients with ISR. However, the value of BVS in this setting remains unclear. METHODS: RIBS VI was a prospective multicenter study (19 Spanish sites) that included 141 patients treated with BVS for either bare-metal stent (BMS) ISR or DES-ISR...
August 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28866035/neoatherosclerosis-as-the-cause%C3%A2-of%C3%A2-late%C3%A2-failure-of-a-bioresorbable%C3%A2-vascular%C3%A2-scaffold-at-8-months
#16
Se Hun Kang, Soo-Jin Kang, Won-Jang Kim
No abstract text is available yet for this article.
August 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28853189/clinical-and-angiographic-outcome-of-a-single-center-real-world-population-treated-with-a-dedicated-technique-of-implantation-for-bioresorbable-vascular-scaffolds-the-fatebenefratelli-bioresorbable-vascular-scaffold-fabs-registry
#17
Bernardo Cortese, Gaetano di Palma, Gregory Dendramis, Enrico Cerrato, Roberto A Latini, Mostafa Elwany, Pedro S Orrego, Romano G Seregni
OBJECTIVES: With this prospective study we aim at investigating the long-term outcome of a consecutive cohort of patients successfully treated with bioresorbable scaffold (BVS) implantation. BACKGROUND: It is not clearly understood if there is a relation between the technique of BVS implantation and the outcome. METHODS: Between December 2012 and December 2014, all consecutive patients treated with BVS were included in this registry and received an angiographic follow-up...
August 29, 2017: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/28845861/-hybrid-percutaneous-coronary-intervention-with-drug-eluting-stent-in-combination-with-bioresorbable-vascular-scaffolds-for-complex-coronary-lesions
#18
Massimo Fineschi, Arcangelo Carrera, Carlo Pierli
Drug-eluting stents (DES) have significantly improved the outcome of percutaneous coronary intervention (PCI); however, several concerns remain regarding late adverse events associated with the presence of a permanent rigid metallic cage that might impair the natural healing process of the coronary vessel wall. Recently, PCI with bioresorbable vascular scaffolds (BVS) has emerged as an interesting alternative with several potential advantages related to the complete resorption process that occurs within 3-5 years...
September 2017: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/28844034/state-of-the-art-the-inception-advent-and-future-of-fully-bioresorbable-scaffolds
#19
Yuki Katagiri, Gregg W Stone, Yoshinobu Onuma, Patrick W Serruys
To overcome the limitations of metallic stents, the development of the bioresorbable vascular scaffold started about 30 years ago. Researchers anticipated a transformative revolution from "vascular reparative therapy" by BRS at the beginning of its development. To date, there are five commercially available bioresorbable scaffolds which have already gained CE mark. However, recent studies, including randomised trials and meta-analyses evaluating clinical results of BRS, have raised concerns about the safety and efficacy of the device in the first few years prior to its complete bioresorption, compared to contemporary metallic DES...
August 25, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28829745/everolimus-eluting-bioresorbable-scaffolds-in-patients-with-coronary-artery-disease-results-from-the-german-austrian-absorb-registry-gabi-r
#20
Holger M Nef, Jens Wiebe, Johannes Kastner, Julinda Mehilli, Thomas Münzel, Christoph Naber, Till Neumann, Gert Richardt, Axel Schmermund, Jochen Wöhrle, Ralf Zahn, Thomas Riemer, Stephan Achenbach, Christian W Hamm
AIMS: To analyze procedural results and mid-term safety of everolimus-eluting bioresorbable vascular scaffolds (BVS) used for percutaneous coronary intervention in a large all-comer cohort from the German-Austrian ABSORB Registry (GABI-R). METHODS AND RESULTS: A total of 3231 patients were included in this prospective, observational, multicentre study (Clinicaltrial.gov NCT02066623) of consecutive patients undergoing BVS implantation between November 2013 and January 2016...
August 22, 2017: EuroIntervention
keyword
keyword
74350
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"